Post-earnings recap
Reported
Fri, May 8, 2026
EPS actual
$-0.71
EPS est.
$-0.58
EPS surprise
-23.26%
1-day move
+0.64%
CG Oncology reported a larger-than-expected loss per share, which may raise concerns among investors about the company's financial health. Despite the miss on EPS, the stock showed no movement, indicating that investors may have anticipated the results. The lack of revenue and guidance adds uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.71 | $-0.54 | -23.26% |
| Revenue | $0M | $0M | N/A |
No transcript is on record for the earnings call, and the analysis is based solely on numerical results.
CG Oncology, Inc. is a biotechnology company focused on developing innovative treatments for cancer. Operating in the health care sector, it aims to address significant unmet medical needs in oncology, making its advancements crucial for patients and the broader medical community.
Last quarter
In Q4-2025, CG Oncology reported an EPS of $-2.08, significantly missing analyst expectations. The stock reacted positively the following day, gaining 4.79%.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-31.88%
Avg 1-day reaction
+1.97%
Analysts expect CG Oncology to report a loss of $-0.54 per share for Q1-2026, with no revenue anticipated. The market is cautious given the company's recent performance.
Bull case
If CG Oncology can exceed expectations on EPS and show signs of revenue generation, it could signal a turnaround, attracting more investor interest.
Bear case
A larger-than-expected loss or continued lack of revenue could lead to further declines in stock price, as investor confidence may wane.
Key metrics to watch
EPS
$-0.54Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$0MRevenue figures will provide insight into the company's market traction and product acceptance.
The print will turn on these.
Q1
Will CG Oncology's EPS come in better than the consensus estimate of $-0.54?
A smaller loss than expected could indicate improving operational efficiency and boost investor confidence.
Q2
Is there any indication of revenue generation this quarter?
Any revenue, even if minimal, would be a positive sign of product acceptance and market traction.
—
Est. EPS
$1.33
Est. Rev
$2.6B
Impl. Move
±8.2%
Why consensus could be wrong
The consensus may underestimate CG Oncology's potential for cost management and operational improvements, which could lead to better-than-expected EPS results.
Supporting evidence
The stock has shown resilience in past quarters despite misses, indicating potential for recovery.
Options pricing suggests a significant move, which may reflect underlying investor optimism not captured in consensus estimates.
Key risk
If the EPS loss is significantly lower than $-0.54, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
The market is closely watching CG Oncology's ability to manage losses and generate revenue, which will significantly influence investor sentiment.
Bull confirmed if
A reported EPS loss of less than $-0.54 would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-0.54 would support the bear case.
What the market is pricing for the move.
Implied Move
±11.69%
Historical Avg
±4.6%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±11.5% while CGON has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
45.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CG Oncology beats EPS estimates, history suggests the stock could rise by around 0.10%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future performance.
Miss
Should the company miss expectations, the stock could drop by approximately 0.83%, indicating ongoing investor concerns.
The lines on the call that would change the story.